Synthesis, molecular Docking and biological evaluation of new 1-Aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenylureas as Potent Type II VEGFR-2 Tyrosine Kinase inhibitors
Artigo de Conferência
Visão geral
Visão geral
resumo
The vascular endothelial growth factor receptor 2 (VEGFR-2) is a tyrosine kinase receptor, expressed primarily in endothelial cells,
and is activated by the specific binding of VEGF to the VEGFR-2 extracellular regulatory domain. Once activated, VEGFR-2 undergoes
autophosphorylation, triggering signaling pathways leading to endothelial cell proliferation and subsequent angiogenesisY1 Small
molecules may act as inhibitors by competing for the ATP-binding s'1te of the VEGFR-2 intracellular tyrosine kinase domain, thereby
preventing the intracellular signa ling that leads to angiogenesis. [ZJ
Here, we present the synthesis of new 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas la-c, as potent type 11 VEGFR-2
inhibitors based on molecular docking (Figure A) and biological evaluation including enzymatic assays using the VEGFR-2 tyrosine kinase
domain (ICso=l0-28 nM) and studies in human umbilical vein endothelial cells (HUVECs). The latter included cell viability (MTS),
proliferation (BrdU) and Western blot for total and phosphorylated VEGFR-2 (Figure B).
The predicted docked poses were analyzed in detail and a plausible explanation for compounds 1 potency was obtained base9 on
the simultaneous presence of a S-linker and the arylurea moiety in the meta position as a new substitution pattern for the type 11
VEGFR-2 inhibitors. These chemical features place the thieno[3,2-b]pyridine and the terminal aryl ring in close superimposition to a
pyrrolo[3,2-d]pyrimidine derivative. The presence of hydrofobic substituents (F and Me) in the terminal aryl ring is also important. For
these compounds a significant inhibition in HUVECs proliferation upon VEGF stimulation was observed at low concentrations (0.5-1.0
IJ.M) without affecting
cell viability. Westernblot
analysis
demonstrated that
compounds 1
significantly
the
inhibited
VEGFR-2
phosphorylation at
1.0 jlM, thus confirming
their anti-angiogenic
potential.
